Abstract: A particle classifier comprising a casing, at least two separating wheels, a guide baffle, and a discharge conduit. The casing has a classification chamber and one or more openings that are provided to conduct air and particulate material into the classification chamber and to discharge course particles therefrom. The separating wheels are mounted in the classification chamber, and each wheel includes a multitude of blades forming openings for conducting fine particles into the interiors of the separating wheels. The guide baffle conducts air and particulate material entrained therewith upward to the separating wheels. The discharge conduit conducts from the separation chamber fine particles passing between the blade of the separating wheels.

Abstract: The present invention provides 3'"-dehydrocardenolide tridigitoxoside oximes of the general formula: ##STR1## in which R.sub.1 is a hydrogen atom or an alkyl radical containing up to 3 carbon atoms, R.sub.2 is a hydrogen atom or a lower acyl or alkyl radical and R.sub.3 represents two hydrogen atoms, the group ##STR2## or the oximino group .dbd.NOR.sub.1, wherein R.sub.1 has the above-given meaning.The present invention also provides a process for the preparation of these oximes, as well as pharmaceutical compostions containing them which are useful for the treatment of cardiac insufficiency.

Abstract: The present invention provides ketals of 3'"-dehydrocardenolide tridigitoxosides of the general formula: ##STR1## in which R.sub.1 and R.sub.2 are identical alkyl radicals containing up to 3 carbon atoms or together represent a cyclic ketal containing 2 to 6 carbon atoms, R.sub.3 represents two hydrogen atoms, the group ##STR2## or the radical ##STR3## wherein R.sub.1 and R.sub.2 have the above-given meaning, and R.sub.4 is a hydrogen atom or a lower acyl or alkyl radical.The present invention also provides processes for the preparation of these ketals, as well as pharmaceutical compositions containing them, which are useful for the treatment of cardiac insufficiency.

Abstract: A pyruvic acid hydrazone derivative of the formula: ##STR1## wherein R is an aryl radical optionally substituted by lower alkyl or is an aliphatic hydrocarbon radical which can be substituted by a lower alkoxy, a cycloalkyl or an optionally substituted aryl radical,A is an alkylene radical containing 2 to 8 carbon atoms, with at least 2 carbon atoms between B and the nitrogen atom, andB is an oxygen or sulphur atom;or a physiologically acceptable salt, ester or amide thereof which possesses hypoglycaemic activity.

Abstract: Cardioactive cardenolide-bis-digitoxosides of the formula ##STR1## in which R.sub.1 is a hydrogen atom, a hydroxyl group or an acyloxy radical containing up to 3 carbon atoms, andR.sub.2, R.sub.3 and R.sub.4 each independently is a hydrogen atom, an acyl radical containing up to 3 carbon atoms,with the proviso that the compound contains at least one alkyl radical. The compounds exhibit desirable rates of excretion, primarily extrarenally.

Abstract: The present invention provides 12-dehydrodigoxin oximes of the general formula: ##STR1## wherein R.sub.1 and R.sub.2, which can be the same or different, are hydrogen atoms, lower acyl radicals or lower alkyl radicals or R.sub.1 and R.sub.2 together can represent an alkylidene radical containing 2 to 6 carbon atoms and R.sub.3 is a hydrogen atom or a lower alkyl or aralkyl radical. The present invention also provides a process for the preparation of these oximes and pharmaceutical compositions containing them and is also concerned with the use of these oximes for the preparation of pharmaceuticals for the treatment of cardiac insufficiency.

Abstract: 12-Epi-digoxins of the formula ##STR1## wherein R.sub.1 and R.sub.2 each independently is hydrogen or a lower alkanoyl or alkyl radical,R.sub.3 is hydrogen or a lower alkanoyl radical, andR.sub.4 is hydrogen or a lower alkyl, alkenyl or alkynyl radical,Are characterized by marked cardioactivity and therapeutic spectrum. They are produced by reduction of the corresponding 12-dehydrodigoxin.

Abstract: A process for the preparation of a C22-alkyl-derivative of digoxin of the formula ##SPC1##In whichR.sub.1 is an alkyl radical containing up to 4 carbon atoms,R.sub.2 and R.sub.3 are selected from the group consisting of hydrogen, acyl, benzyl, carbobenzoxy, trimethylsilyl, tetrahydropyranyl or phosphonoacyl radicals or together form an alkylidene radical,Comprising reacting a compound of the formula ##SPC2##With an alkyl iodide of the formula R.sub.1 I in the presence of a strongly polar aprotic solvent and an alkali metal hydride. If R.sub.2 and R.sub.3 are other than hydrogen they can subsequently be replaced by hydrogen by hydrolysis or hydrogenation. The product can be .alpha.- or .beta.-methylated to produce compounds of high resorption and low toxicity.

Abstract: New dihydrodigoxin derivatives of the formula ##SPC1##Wherein one of R.sub.1 and R.sub.2 represents a methyl or ethyl radical and the other represents hydrogen, methyl, ethyl or acetyl (i.e. alkanoyl; and R.sub.3 is hydrogen or an acetyl group; are outstandingly effective for therapy of cardiac insufficiencies, particularly via peroral administration.